GlassScriptPhysician profile
Rachael A Cunnick
NPI 1972697753
$3,280.42
in general payments reported to CMS, 2019-2025
27 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $507 · 2023: $1,246 · 2024: $684 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,375 · Consulting Fee: $70.00 · Long Term Medical Supply Or Device Loan: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.00 |
| Consulting Fee | $70.00 |
| Long Term Medical Supply Or Device Loan | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $460.06 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $402.74 | 2023-2025 | Minimed 780g |
| Novo Nordisk INC | $397.59 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.60 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $191.33 | 2022-2023 | |
| Abbott Laboratories | $154.77 | 2021-2024 | Freestyle Insulinx, Freestyle Libre 3 |
| Insulet Corporation | $153.99 | 2022-2025 | Omnipod |
| Phathom Pharmaceuticals, INC. | $117.11 | 2024 | Voquezna |
| Abbvie INC. | $111.72 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $105.77 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $103.64 | 2021-2023 | Belsomra, Steglatro |
| Xeris Pharmaceuticals, INC. | $99.90 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $99.67 | 2022-2025 | Entresto, Leqvio |
| Dexcom, INC. | $90.53 | 2022-2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $62.16 | 2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $55.56 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $45.08 | 2021-2025 | Farxiga, Breztri |
| Astellas Pharma US INC | $42.72 | 2025 | Veozah |
| Baxter Healthcare | $36.25 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Otsuka America Pharmaceutical, INC. | $33.83 | 2024 | Rexulti |
| Amgen INC. | $32.86 | 2023-2024 | Prolia, Evenity, Repatha |
| Kyowa Kirin, INC. | $25.88 | 2023 | Crysvita |
| Recordati_rare_diseases_inc. | $21.37 | 2023 | Signifor Lar, Isturisa |
| Averitas Pharma INC. | $20.49 | 2023 | Qutenza |
| Exact Sciences Corporation | $19.41 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $16.59 | 2025 | |
| Exeltis, USA INC. | $13.80 | 2025 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Cunnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.